Greenwich LifeSciences, Inc.’s GLSI share price has dipped by 5.17%, which has investors questioning if this is right time to ...

STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial ...

GREENWICH LIFESCIENCES ($GLSI) is expected to release its quarterly earnings data on Monday, April 14th after market close, per Finnhub. Analysts are expecting ...

We suggest investors evaluate other financial metrics to understand its overall valuation. Greenwich LifeSciences, Inc.’s (GLSI) price is currently down 2.73% so far this month. During the month of ...

At close: 15 April at 4:00:01 pm GMT-4 ...

Liquidia Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat ...